Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Total Non-Current Liabilities: 2022-2025

Historic Total Non-Current Liabilities for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $505.7 million.

  • Axsome Therapeutics' Total Non-Current Liabilities rose 31.14% to $505.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.7 million, marking a year-over-year increase of 31.14%. This contributed to the annual value of $419.8 million for FY2024, which is 29.59% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Total Non-Current Liabilities is $505.7 million, which was up 3.82% from $487.1 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Total Non-Current Liabilities registered a high of $505.7 million during Q3 2025, and its lowest value of $136.0 million during Q2 2022.
  • Its 3-year average for Total Non-Current Liabilities is $375.4 million, with a median of $375.8 million in 2024.
  • Data for Axsome Therapeutics' Total Non-Current Liabilities shows a peak YoY surged of 120.05% (in 2023) over the last 5 years.
  • Over the past 4 years, Axsome Therapeutics' Total Non-Current Liabilities (Quarterly) stood at $190.8 million in 2022, then soared by 69.77% to $324.0 million in 2023, then climbed by 29.59% to $419.8 million in 2024, then soared by 31.14% to $505.7 million in 2025.
  • Its Total Non-Current Liabilities stands at $505.7 million for Q3 2025, versus $487.1 million for Q2 2025 and $452.9 million for Q1 2025.